Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm - DexCom ( NASDAQ:DXCM )
NEW YORK, Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. ( NASDAQ:DXCM ) breached their fiduciary duties to shareholders.
Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?
PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM - DexCom ( NASDAQ:DXCM )
NEW YORK, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ( "DexCom" or the "Company" ) DXCM. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
1 Growth Stock Down 40% to Buy Hand Over Fist Right Now
It is dealing with some short-term issues, but its prospects remain bright.
Which Stocks Win When Rates Fall? Goldman Picks These Surprising Names - Arista Networks ( NYSE:ANET ) , Axon Enterprise ( NASDAQ:AXON )
With Wall Street indices hitting fresh records and the Fed embracing a dovish pivot with further rate cuts on the table, Goldman Sachs wasted no time upgrading its S&P 500 target-but it's the bank's unusual stock picks that stand out.
Spotlight on DexCom: Analyzing the Surge in Options Activity - DexCom ( NASDAQ:DXCM )
Deep-pocketed investors have adopted a bearish approach towards DexCom DXCM, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
Practice of law: case studies
Featuring the most innovative work and legal service lawyers have developed for their clients ...
Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA - DexCom ( NASDAQ:DXCM )
At least 60 Dexcom G7 users report hospitalization, with multiple deaths alleged. FDA cited Dexcom for unauthorized material changes that impacted accuracy. Up Next: Wall Street trader's 35-0 strategy goes public this week. See it first → Hunterbrook Media released a short report on ...
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - DexCom ( NASDAQ:DXCM )
NEW YORK, Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DexCom, Inc.
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm - DexCom ( NASDAQ:DXCM )
NEW YORK, Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. DXCM breached their fiduciary duties to shareholders.
Investing in the Age of Longevity: Silver Economy Stocks in Focus
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
Why Is DexCom ( DXCM ) Down 7% Since Last Earnings Report?
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
P/E Ratio Insights for DexCom - DexCom ( NASDAQ:DXCM )
Looking into the current session, DexCom Inc. DXCM shares are trading at $75.05, after a 0.04% decrease. Over the past month, the stock fell by 5.65%, but over the past year, it actually spiked by 3.37%.
If You'd Invested $1,000 in DexCom 10 Years Ago, Here's How Much You'd Have Today
The company's innovative devices have helped it generate decent performances.
DexCom Expands Access and Innovation While Balancing Headwinds
DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.
FDA approves first-ever glucose monitoring system for weight loss from Signos
Any patient can access Signos' system, which uses an AI platform and an off-the-shelf continuous glucose monitor, or CGM, from Dexcom.
2 Stocks to Buy on the Dip and Hold for 10 Years
There should be plenty of long-term upside for these stocks for investors willing to ride out the storm.
Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data
TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.
Insulet ( PODD ) Q2 Revenue Jumps 33%
Insulet ( NASDAQ:PODD ) , a medical device company specializing in wearable insulin delivery systems, released its second quarter 2025 earnings on August 7, 2025. The headline news was strong outperformance: GAAP revenue rose to $649.1 million, beating estimates by nearly $35 million, while ...
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - DexCom ( NASDAQ:DXCM )
NEW YORK, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DexCom, Inc.
Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?
ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.
DexCom ( DXCM ) Q2 Revenue Jumps 15%
DexCom ( NASDAQ:DXCM ) reported its second-quarter 2025 results on July 30, 2025, delivering an upbeat performance highlighted by a revenue beat and continued expansion in the key type 2 diabetes market. The maker of continuous glucose monitoring ( CGM ) systems posted GAAP revenue of $1.16 ...
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
DexCom ( DXCM ) Q2 Earnings and Revenues Top Estimates
DexCom (DXCM) delivered earnings and revenue surprises of +6.67% and +3.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
DexCom ( DXCM ) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Besides Wall Street's top-and-bottom-line estimates for DexCom (DXCM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?
DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
Are Medical Stocks Lagging DexCom ( DXCM ) This Year?
Here is how DexCom (DXCM) and Amarin (AMRN) have performed compared to their sector so far this year.
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years
Medical device specialist DexCom ( NASDAQ: DXCM ) has encountered significant headwinds in the past year. The company's financial results haven't been quite up to the market's standards, and broader market volatility caused by President Donald Trump's trade policies isn't helping either.
2 No-Brainer ETFs to Build Your Portfolio Around
If you're getting started with investing, or if you just want to add some pillars that you can build your portfolio around, investing in a couple of exchange-traded funds ( ETFs ) can make the process easy. By focusing on dividends and long-term growth, you can ensure you're getting a good mix of ...
DexCom ( DXCM ) Upgraded to Strong Buy: Here's What You Should Know
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes - Eli Lilly ( NYSE:LLY ) , DexCom ( NASDAQ:DXCM )
In a public post in May, I wrote about Sana Biotechnology, Inc. SANA, a biotech that has developed a potential cure for type 1 diabetes. Here's an update on developments since. Functional-cure potential. Sana's hypo-immune ( HIP ) edits let donor islet cells make insulin without triggering ...
Check Out What Whales Are Doing With DXCM - DexCom ( NASDAQ:DXCM )
Investors with a lot of money to spend have taken a bearish stance on DexCom DXCM. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders - DexCom ( NASDAQ:DXCM )
SAN DIEGO, July 09, 2025 ( GLOBE NEWSWIRE ) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. DXCM for potential breaches of fiduciary duties and violations of the federal securities laws.
What Does the Market Think About DexCom? - DexCom ( NASDAQ:DXCM )
DexCom's DXCM short percent of float has fallen 10.0% since its last report. The company recently reported that it has 9.38 million shares sold short, which is 3.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.8 days to cover their ...
2 Stocks to Buy on the Dip and Hold for 10 Years
One of Warren Buffett's famous pieces of investing advice is to be greedy when others are fearful. One way to apply this wisdom is to look for companies that have lagged the market recently but still appear to be excellent long-term investment opportunities.Two great examples today in the ...
Is DexCom ( DXCM ) Stock Outpacing Its Medical Peers This Year?
Here is how DexCom (DXCM) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
3 Reasons Growth Investors Will Love DexCom ( DXCM )
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Nasdaq Welcomes 142 IPOs in the First Half of 2025
Highest volume of listings and capital raise in the first half of the year since ...
Nasdaq Welcomes 142 IPOs in the First Half of 2025
Nasdaq Welcomes 142 IPOs in the First Half of ...
Nasdaq Welcomes 142 IPOs in the First Half of 2025 - Nasdaq ( NASDAQ:NDAQ )
Highest volume of listings and capital raise in the first half of the year since 2021 Maintained leadership in switches - crossed $3 trillion in market value transferred since 2005 Driving smart policy reforms to improve regulatory processes for public companies
Price Over Earnings Overview: DexCom - DexCom ( NASDAQ:DXCM )
In the current session, DexCom Inc. DXCM is trading at $86.18, after a 1.59% decrease. Over the past month, the stock decreased by 0.92%, and in the past year, by 24.76%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio.
DXCM's Access Gains and Operational Strength Offset Margin Pressures
DXCM rides on record patient growth and T2D access gains, but margin pressure and FDA scrutiny cloud the outlook.
Medtronic Is Separating Its Diabetes Business - Good News For Investors - Medtronic ( NYSE:MDT )
Medtronic plc MDT announced on May 21 its plans to separate its Diabetes business into a separate, publicly traded company. The separation will occur via a two step transaction - an initial minority IPO carve-out followed by a split-off of the remaining stake.
Here's Why You Should Retain PODD Stock in Your Portfolio Now
Insulet's Omnipod 5 gains traction with global expansion and rising Type 2 adoption despite economic and competitive hurdles.
Is Invesco S&P 500 Equal Weight Health Care ETF ( RSPH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Beta Bionics ( NASDAQ:BBNX ) , Insulet ( NASDAQ:PODD ) , DexCom ( NASDAQ:DXCM )
Goldman sets $380 target for Insulet, citing Omnipod's unique design and share capture potential. Dexcom gets $104 target, expected to gain share in non-insulin diabetes segments through 2025. Rebound or breakdown? See how Matt Maley is trading June's market volatility, live this Wednesday, June ...
Does This Move Make Medtronic Stock a Buy?
Over the past few years, Medtronic ( NYSE: MDT ) has faced significant challenges, including a pandemic-induced slowdown, relatively slow revenue growth, and economic issues that impacted its financial results. Throughout it all, Medtronic's diabetes care business has consistently been one of its ...
Continuous Glucose Monitoring Devices Market Size expected to reach US$ 32.97 billion by 2031, Increasing Demand for Effective Diabetes Management Propels Growth
US & Canada, May 30, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the global continuous glucose monitoring devices market is observing significant growth owing to the increasing demand for effective diabetes management and the growing use of OTC ...
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack ...
